Evidence map›Paper›PMID 36534154›Full record

ArticleWorld journal of urology2023

Functional outcomes of GreenLight 180-W photoselective vaporization in patients with large (≥ 80 cc) prostates: an analysis of over 3000 men in the Global Greenlight Group (GGG) database.

Nicholas Corsi, David-Dan Nguyen, Adel Arezki, Iman Sadri, Kyle Law, David Bouhadana, Claudia Deyirmendjian, Naeem Bhojani, Dean S Elterman, Franck Bruyère and 11 more

Abstract read
PubMed Publisher
In one paragraph

Article in World journal of urology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 13 institutions in 7 countries.

Nicholas Corsi *Wayne State University School of Medicine, Detroit, Michigan, USA.ORCID http://orcid.org/0000-0001-6190-1329
David-Dan Nguyen *Division of Urology, University of Toronto, Toronto, ON, Canada.ORCID http://orcid.org/0000-0001-5570-8792
Adel ArezkiDivision of Urology, McGill University, Montreal, QC, Canada.ORCID http://orcid.org/0000-0002-9022-0677
Iman SadriDivision of Urology, McGill University, Montreal, QC, Canada.ORCID http://orcid.org/0000-0003-1399-7527
Kyle LawDivision of Urology, Université de Montréal, Montreal, QC, Canada.
David BouhadanaFaculty of Medicine and Health Sciences, McGill University, Montreal, QC, Canada.
Claudia DeyirmendjianDivision of Urology, Université de Montréal, Montreal, QC, Canada.
Naeem BhojaniDivision of Urology, Université de Montréal, Montreal, QC, Canada.
Dean S EltermanDivision of Urology, University of Toronto, Toronto, ON, Canada.
Franck BruyèreDepartment of Oncology and Urology, Centre Hospitalier Universitaire de Tours, Tours, France.
Luca CindoloDepartment of Urology, Hesperia Hospital, Cure Group, Modena, Italy.ORCID http://orcid.org/0000-0002-0712-2719
Giovanni FerrariDepartment of Urology, Hesperia Hospital, Cure Group, Modena, Italy.
Carlos Vasquez-LastraDepartment of Urology, ABC Medical Center, Mexico City, Mexico.
Tiago Borelli-BovoBorelli Urologia, Ribeirão Presto, Sao Paulo, Brazil.
Edgardo F BecherCentro de Urologia, CDU, Buenos Aires, Argentina.
Hannes CashDepartment of Urology, University of Magdeburg, Madeburg, Germany.
Maximillian ReimannDepartment of Urology, Charité-Universitaetsmedizin Berlin, Berlin, Germany.
Enrique RijoDepartment of Urology, Hospital Quiron Barcelona, Barcelona, Spain.
Vincent MisraiDepartment of Urology, Clinique Pasteur, Toulouse, France.
Bilal ChughtaiDepartment of Urology, Weill Cornell Medical College, New York Presbyterian, New York, USA.
Kevin C ZornDivision of Urology, Université de Montréal, Montreal, QC, Canada. zorn.chumurology@gmail.com.
Université de Montréal · CAHesperia Hospital · ITMcGill University · CAUniversity of Toronto · CACentre Hospitalier Universitaire de Tours · FRCentro Médico ABC · MXCharité - Universitätsmedizin Berlin · DEClinique Pasteur · FRCornell University · USHospital Quirónsalud Barcelona · ESMcGill University Health Centre · CAUniversity Hospital Magdeburg · DEWayne State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionGreenLight photoselective vaporization of the prostate (PVP) has gained widespread adoption as an option to traditional transurethral resection of the prostate. Prior reports expressed concern with the use of PVP in large prostates. The aim of this study was to investigate the adjusted outcomes of GreenLight PVP in men with large (≥ 80 cc) vs. small prostates (< 80 cc).

methodsData were obtained from the Global Greenlight Group which pools data from 7 high volume centers. Men with established benign prostatic hyperplasia who underwent GreenLight PVP using the XPS-180 W system between 2011 and 2019 were eligible and assigned into two groups based on their prostate size (≥ 80 and < 80 cc). 11 functional and perioperative covariates were collected. Analyses were adjusted for patient age and presence of median lobe.

results3426 men met the inclusion criteria. 34.6% (n = 1187) of patients had a large prostate size. Baseline age and prostate volume were significantly different between the groups. The magnitude of absolute improvement in unadjusted international prostate symptom score was significantly greater in the large (≥ 80 cc) prostate group at 12 months, with an absolute change of 19.17 points (95% CI 18.46-19.88; p < 0.01). There was also a significant drop in PVR at both 6- (p = 0.007) and 12 months (p = 0.005). There were no significant differences in transfusion (p = 0.42), hematuria (p = 0.80), or 30-day readmission rates (p = 0.28).

conclusionsGreenlight PVP is a safe and effective alternative for patients with prostate sizes ≥ 80 cc, with durable outcomes relatively independent from prostate size.

Indexed as

Laser TherapyProstatic HyperplasiaTransurethral Resection of ProstateHumansMaleProstateTreatment OutcomeVolatilizationBPHGreenLightIPSSLarge prostatePhotoselective vaporization of the prostate

Identifiers

PMID36534154
OpenAlexW4311927821

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.